Treatment

SUN-627, SUN-627, SUN-627 clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedTherapeutic exploratory (Phase II)
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
This study is looking at a new medicine called SUN-627 for people with certain types of Multiple Sclerosis (MS). Researchers want to see if it's safe, how the body uses it, and if it helps reduce inflammation in the brain over 16 weeks.
For: Multiple Sclerosis · Primary Progressive Multiple Sclerosis · non-active Secondary Progressive Multiple Sclerosis
Finland